These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 12431963)

  • 1. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
    Orlowski RZ; Stinchcombe TE; Mitchell BS; Shea TC; Baldwin AS; Stahl S; Adams J; Esseltine DL; Elliott PJ; Pien CS; Guerciolini R; Anderson JK; Depcik-Smith ND; Bhagat R; Lehman MJ; Novick SC; O'Connor OA; Soignet SL
    J Clin Oncol; 2002 Nov; 20(22):4420-7. PubMed ID: 12431963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
    Dy GK; Thomas JP; Wilding G; Bruzek L; Mandrekar S; Erlichman C; Alberti D; Binger K; Pitot HC; Alberts SR; Hanson LJ; Marnocha R; Tutsch K; Kaufmann SH; Adjei AA
    Clin Cancer Res; 2005 May; 11(9):3410-6. PubMed ID: 15867242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
    Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
    J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.
    Hamilton AL; Eder JP; Pavlick AC; Clark JW; Liebes L; Garcia-Carbonero R; Chachoua A; Ryan DP; Soma V; Farrell K; Kinchla N; Boyden J; Yee H; Zeleniuch-Jacquotte A; Wright J; Elliott P; Adams J; Muggia FM
    J Clin Oncol; 2005 Sep; 23(25):6107-16. PubMed ID: 16135477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).
    Blaney SM; Bernstein M; Neville K; Ginsberg J; Kitchen B; Horton T; Berg SL; Krailo M; Adamson PC
    J Clin Oncol; 2004 Dec; 22(23):4804-9. PubMed ID: 15570082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
    Davis NB; Taber DA; Ansari RH; Ryan CW; George C; Vokes EE; Vogelzang NJ; Stadler WM
    J Clin Oncol; 2004 Jan; 22(1):115-9. PubMed ID: 14701773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.
    Holkova B; Perkins EB; Ramakrishnan V; Tombes MB; Shrader E; Talreja N; Wellons MD; Hogan KT; Roodman GD; Coppola D; Kang L; Dawson J; Stuart RK; Peer C; Figg WD; Kolla S; Doyle A; Wright J; Sullivan DM; Roberts JD; Grant S
    Clin Cancer Res; 2011 May; 17(10):3388-97. PubMed ID: 21447728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
    Ma C; Mandrekar SJ; Alberts SR; Croghan GA; Jatoi A; Reid JM; Hanson LJ; Bruzek L; Tan AD; Pitot HC; Erlichman C; Wright JJ; Adjei AA
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):207-15. PubMed ID: 16763792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibition in hematologic malignancies.
    Richardson PG; Hideshima T; Mitsiades C; Anderson K
    Ann Med; 2004; 36(4):304-14. PubMed ID: 15224657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 study of bortezomib in relapsed, refractory myeloma.
    Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
    N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas.
    O'Connor OA
    Curr Treat Options Oncol; 2004 Aug; 5(4):269-81. PubMed ID: 15233904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
    Orlowski RZ; Voorhees PM; Garcia RA; Hall MD; Kudrik FJ; Allred T; Johri AR; Jones PE; Ivanova A; Van Deventer HW; Gabriel DA; Shea TC; Mitchell BS; Adams J; Esseltine DL; Trehu EG; Green M; Lehman MJ; Natoli S; Collins JM; Lindley CM; Dees EC
    Blood; 2005 Apr; 105(8):3058-65. PubMed ID: 15626743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
    Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
    Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Proteasome inhibition: a new therapeutic approach for the treatment of multiple myeloma].
    Mikala G; Jákó J; Vályi-Nagy I
    Orv Hetil; 2004 Jan; 145(2):67-74. PubMed ID: 14978877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical update: proteasome inhibitors in hematologic malignancies.
    Richardson P
    Cancer Treat Rev; 2003 May; 29 Suppl 1():33-9. PubMed ID: 12738241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
    LoConte NK; Thomas JP; Alberti D; Heideman J; Binger K; Marnocha R; Utecht K; Geiger P; Eickhoff J; Wilding G; Kolesar J
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):109-15. PubMed ID: 18322686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
    Ryan DP; Appleman LJ; Lynch T; Supko JG; Fidias P; Clark JW; Fishman M; Zhu AX; Enzinger PC; Kashala O; Cusack J; Eder JP
    Cancer; 2006 Nov; 107(10):2482-9. PubMed ID: 17036355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential for proteasome inhibition in the treatment of cancer.
    Adams J
    Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.
    Reece DE; Sanchorawala V; Hegenbart U; Merlini G; Palladini G; Fermand JP; Vescio RA; Liu X; Elsayed YA; Cakana A; Comenzo RL;
    Blood; 2009 Aug; 114(8):1489-97. PubMed ID: 19498019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibition in cancer: development of PS-341.
    Adams J
    Semin Oncol; 2001 Dec; 28(6):613-9. PubMed ID: 11740819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.